Evidence map›Paper›PMID 25379707›Full record

ArticlePloS one2014

Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern.

Veronica Mariotti, Erika Melissari, Caterina Iofrida, Marco Righi, Manuela Di Russo, Riccardo Donzelli, Alessandro Saba, Sabina Frascarelli, Grazia Chiellini, Riccardo Zucchi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. 3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?International journal of molecular sciences · 2020
    Review
  7. Novel thyroid hormones.Endocrine · 2019
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Veronica MariottiDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Erika MelissariDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Caterina IofridaDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Marco RighiDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Manuela Di RussoDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Riccardo DonzelliDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Alessandro SabaDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Sabina FrascarelliDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Grazia ChielliniDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Riccardo ZucchiDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
Silvia PellegriniDepartment of Surgical, Medical, Molecular Pathology and of Critical Care, University of Pisa, Pisa, Italy.
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

3-Iodothyronamine (T1AM) is an endogenous biogenic amine, structurally related to thyroid hormone, which is regarded as a novel chemical messenger. The molecular mechanisms underlying T1AM effects are not known, but it is possible to envisage changes in gene expression, since delayed and long-lasting phenotypic effects have been reported, particularly with regard to the modulation of lipid metabolism and body weight. To test this hypothesis we analysed gene expression profiles in adipose tissue and liver of eight rats chronically treated with T1AM (10 mg/Kg twice a day for five days) as compared with eight untreated rats. In vivo T1AM administration produced significant transcriptional effects, since 378 genes were differentially expressed in adipose tissue, and 114 in liver. The reported changes in gene expression are expected to stimulate lipolysis and beta-oxidation, while inhibiting adipogenesis. T1AM also influenced the expression of several genes linked to lipoprotein metabolism suggesting that it may play an important role in the regulation of cholesterol homeostasis. No effect on the expression of genes linked to toxicity was observed. The assay of tissue T1AM showed that in treated animals its endogenous concentration increased by about one order of magnitude, without significant changes in tissue thyroid hormone concentration. Therefore, the effects that we observed might have physiological or pathophysiological importance. Our results provide the basis for the reported effectiveness of T1AM as a lipolytic agent and gain importance in view of a possible clinical use of T1AM in obesity and/or dyslipidaemia.

Indexed as

Adipose TissueAnimalsGene Expression RegulationLipolysisLiverMaleRatsRats, WistarThyroninesTranscription, Genetic3-iodothyronamineThyronines

Identifiers

PMID25379707
PMCPMC4224367
OpenAlexW2086120926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.